Ocuphire Pharma

Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for various ophthalmic disorders. Its lead product candidate, Nyxol eye drops, is a once-daily preservative-free formulation of phentolamine mesylate aimed at reducing pupil size for indications such as night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia.

Rexahn Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company is headquartered in Rockville, Maryland, and aims to improve the lives of cancer patients by creating next-generation cancer therapies that enhance efficacy while reducing side effects. Rexahn's product pipeline includes RX-3117, currently in Phase IIa clinical trials for relapsed or refractory metastatic pancreatic cancer, as well as other cancers such as bladder, colon, lung, and cervical cancer. In addition, Rexahn is advancing RX-0301, a preclinical drug candidate for hepatocellular carcinoma. The company has established collaboration agreements with various organizations, including Zhejiang Haichang Biotechnology Co., Ltd., and BioSense Global LLC, to further its research and development efforts.